Benchmark raised the firm’s price target on Nutex Health (NUTX) to $300 from $150 and keeps a Buy rating on the shares based on “another big beat” in Q1 and positive updates to the firm’s model. Based on greater visibility into the sustainability of rate arbitration success realization, the firm is “significantly lifting” its FY25 and FY26 outlooks for revenue, adjusted EBITDA and GAAP EPS, the analyst tells investors, adding that Nutex remains a “Benchmark Best Idea.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUTX:
- Nutex Health Reports Strong Q1 2025 Financial Growth
- Clinigence Holdings’ Strong Financial Performance and Strategic Successes Drive Buy Rating
- Nutex Health reports Q1 EPS $2.56 vs. (8c) last year
- Nutex Health up 10% afterhours at $138 per share following Q1 results
- Nutex Health files to sell 78,424 shares of common stock for holders